Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01152554 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 813
- Enrollment target
NCT01152554 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 813 participants.
The verdict
NCT01152554, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 813 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken for 52 weeks with another antidepressant medicine.
Interventions
- DRUG Placebo
- DRUG TC-5214
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 813 participants |
| Start Date | 2010-06 |
| Est. Completion | 2012-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01152554
The ClinicalTrials.gov registry entry for NCT01152554 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 813 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01152554 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01152554 about?
NCT01152554 is a clinical study titled "A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder". The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken for 52 weeks with another antidepressant medicine.
What is the current status of trial NCT01152554?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 813 participants. The study started on 2010-06. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01152554?
The interventions under investigation include: Placebo (DRUG), TC-5214 (DRUG).
Who is sponsoring clinical trial NCT01152554?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.